Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1

Clinical Cancer Research

Volumn 12, Issue 24, 2006, Pages 7476-7482

  Asemissen, Anne Marie ^a   Keilholz, Ulrich ^a   Tenzer, Stefan ^b   Müller, Margret ^c   Walter, Steffen ^c   Stevanovic, Stefan ^c   Schild, Hansjörg ^b   Letsch, Anne ^a   Thiel, Eckhard ^a   Rammensee, Hans Georg ^c   Scheibenbogen, Carmen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; PROTEIN WT1; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMETRY; CYTOTOXIC LYMPHOCYTE; DRUG IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; LUNG CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

EID: 33846253186     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1337     Document Type: Article

References (49)

1. Keilholz U, Menssen HD, Gaiger A, et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005;19:1318-23.
2. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405-12.
3. Loeb DM, Evron E, Patel CB, et al. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001;61:921-5.
4. Azuma T, Otsuki T, Kuzushima K, Froelich CJ, Fujita S, Yasukawa M. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2004;10: 7402-12.
5. Oji Y, Miyoshi S, Maeda H, et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002;100:297-303.
6. Koesters R, Linnebacher M, Coy JF, et al. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 2004;109:385-92.
7. Nakatsuka SI, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006;19:804-14.
8. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996;12:1005-14.
9. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90: 194-204.
10. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95:2198-203.
11. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002;51: 614-20.
12. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000;96:1480-9.
13. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-7.
14. Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99:3272-9.
15. Gentilini C, Hilbers U, Ganepola S, et al. WT1-specific T cell responses are frequent after allogeneic stem cell transplantation for acute and chronic myeloid leukemia. Blood 2005;106:2906.
16. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892-900.
17. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004;18:165-6.
18. Oka Y, Tsuboi A, Taguchi T, et al. Kawakami M lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004; 101:13885-90.
19. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A*0201- presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002;100:3835-7.
20. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000;51:99-107.
21. Azuma T, Makita M, Ninomiya K, et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2002;116: 601-3.
22. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997;9:681-3.
23. Scheibenbogen C, Sun Y, Keilholz U, et al. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 2002;98:409-4.
24. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002;99:3830-7.
25. Reynolds SR, Celis E, Sette A, et al. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J Immunol Methods 2000;244:59-67.
26. Ghei M, Stroncek DF, Provenzano M. Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides. J Transl Med 2005;3:23.
27. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001; 193:73-88.
28. Lucchiari-Hartz M, van Endert PM, Lauvau G, et al. Cytotoxic T lymphocyte epitopes o HIV-1 Nef: generation of multiple definitive major histocompatibility complex class I ligands by proteasomes. J Exp Med 2000;191:239-52.
29. Baur MP, Neugebauer M, Albert ED. Reference tables of two-locus haplotype frequencies for all MHC marker loci. In: Albert, et al., editor. Histocompatibility testing. Springer-Verlag, Berlin, Heidelberg; 1984. p. 677-81.
30. Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743-50.
31. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9.
32. Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keilholz U, Thiel E. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2004;83:745-50.
33. Moris A, Teichgräber V, Gauthier L, Bühring HJ, Rammensee HG. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol 2001;166: 4818-21.
34. Bodinier M, Peyrat MA, Tournay C, et al. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat Med 2000;6:707-10.
35. Tenzer S, Stoltze L, Schonfisch B, et al. Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J Immunol 2004;172:1083-91.
36. Scheibenbogen C, Romero P, Rivoltini L, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNγ-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 2000;244:81-9.
37. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999;50: 201-12.
38. Mo XY, Cascio P, Lemerise K, Goldberg AL, Rock K. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J Immunol 1999;163-5851-9.
39. Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005;106:1008-11.
40. Coulie PG. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today 1997;3:261-8
41. Sun Y, Stevanovic S, Song M, et al. The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Blood 2006;107:1476-83
42. Neumann F, Wagner C, Preuss KD, et al. Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells. Blood 2005;106: 3105-13.
43. Kruger T, Schoor O, Lemmel C, et al. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy Cancer Immunol Immunother 2005;54:826-36.
44. Ayyoub M, Stevanovic S, Sahin U, et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 2002;168:1717-22.
45. Morel S, Levy F, Burlet-Schiltz O, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000;12:107-17.
46. Van den Eynde BJ, Morel S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol 2001;13:147-53.
47. Snyder HL, Yewdell JW, Bennink JR. Trimming of antigenic peptides in an early secretory compartment. J Exp Med 1994;180:2389-94.
48. Nishikawa H, Qian F, Tsuji T, et al. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J Immunol 2006;176:6340-6
49. Gillmore R, Xue SA, Holler A, et al. Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res 2006;12:34-42.